# Alopecia areata: from immunopathogenesis to emerging therapeutic approaches

## TL;DR

This paper reviews the immune mechanisms behind alopecia areata and explores new treatment options beyond traditional therapies.

## Contribution

The paper introduces emerging immunomodulatory strategies and novel therapeutic targets for alopecia areata.

## Key findings

- NKG2D+CD8+ T cells are central to alopecia areata's immunopathogenesis.
- JAK inhibitors show promise but are limited by high relapse rates.
- Neutralizing antibodies and S1P receptor modulators are emerging as potential therapies.

## Abstract

Alopecia areata (AA) is a non-scarring inflammatory hair loss disorder characterized by a T-cell–mediated autoimmune disease that targets the hair follicles. In particular, Natural Killer Group 2 member D (NKG2D)+CD8+ T cells have been identified as central players in its pathogenesis. Current treatment options have limited efficacy and are often associated with adverse effects and high risk of relapse upon discontinuation, highlighting the need for targeted and durable therapeutic strategies. Janus kinase (JAK) inhibitors have emerged as representative therapies; however, they are limited by a high relapse rate after treatment cessation. Recently, novel therapeutic approaches such as neutralizing antibodies targeting cytokines and chemokines, and sphingosine-1-phosphate (S1P) receptor modulators have gained attention. Various molecular markers associated with AA have been identified as potential therapeutic targets. This review provides a comprehensive overview of the roles of immune cells in AA pathogenesis and introduces emerging immunomodulatory strategies and novel therapeutic targets.